CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)

• Status: RECRUITING
• Trial end date: 2026-12-31

Summary

A Clinical Study Exploring CT1190B in the treatment of patients with moderate to severe refractory systemic lupus erythematosus (SLE) or refractory/progressive systemic sclerosis (SSc)

• Phase: PHASE1

Details

• Lead Sponsor: Beijing GoBroad Hospital
• Collaborator: CARsgen Therapeutics Co., Ltd.
• Treatments: Immunotherapy, Adoptive